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Outcome reporting bias in trials: a methodological approach for 
assessment and adjustment in systematic reviews
Jamie J Kirkham,1 Douglas G Altman,2 An-Wen Chan,3 Carrol Gamble,1 Kerry M Dwan,4  
Paula R Williamson1
Systematic reviews of clinical trials aim 
to include all relevant studies 
conducted on a particular topic and to 
provide an unbiased summary of their 
results, producing the best evidence 
about the benefits and harms of 
medical treatments. Relevant studies, 
however, may not provide the results 
for all measured outcomes or may 
selectively report only some of the 
analyses undertaken, leading to 
unnecessary waste in the production 
and reporting of research, and 
potentially biasing the conclusions to 
systematic reviews. In this article, 
Kirkham and colleagues provide a 
methodological approach, with an 
example of how to identify missing 
outcome data and how to assess and 
adjust for outcome reporting bias in 
systematic reviews.
“Trials that presented findings that were not significant 
(P≥0.05) for the protocol-defined primary outcome in 
the internal documents either were not reported in full 
or were reported with a changed primary outcome.”1
Selective reporting of outcome data creates a 
missing data problem. Bias arises when trialists select 
outcome results for publication based on knowledge 
of the results. Hutton and Williamson first defined 
outcome reporting bias (sometimes termed selective 
reporting bias) in 2000: “the selection on the basis of 
the results of a subset of the original variables recorded 
for inclusion in a publication.”2
Empirical research provides strong evidence that 
outcomes that are statistically significant have higher 
odds of being fully reported than non-significant 
outcomes (odds ratios ranging from 2.2 to 4.7).3  4 In 
the ORBIT (Outcome Reporting Bias In Trials) study, 
outcome reporting bias was suspected in at least one 
trial in more than a third (96/283; 34%) of Cochrane 
systematic reviews.5 In the follow-up study that looked 
at the same problem in a review of harm outcomes, 
review primary harm outcome data were missing from 
at least one eligible study in over 75% (252/322)of 
systematic reviews.6
The aim of this article is to show, with an example, 
how systematic reviewers can minimise the amount of 
missing data in reviews of healthcare interventions, 
and use ORBIT methods to detect and classify the 
suspicion of outcome reporting bias in benefits and 
harms reported in included studies. The paper also 
provides details of a statistical approach to assess 
the robustness of meta-analysis conclusions on this 
potential source of bias that non-methodologists can 
implement on a web based platform.
Selecting the most appropriate review outcomes
One way to streamline the process of systematic 
reviews and to help reduce outcome reporting bias is 
for reviewers to use outcomes considered as core for all 
trials in a particular topic area.7 These core outcome 
sets will ensure that every included trial can contribute 
data on key outcomes to the review analyses. An 
example is a set of core outcomes that have been 
developed for different skin conditions, which has 
now been endorsed by the Cochrane Skin Group Core 
Outcome Set Initiative (CSG-COUSIN).8
We recommend that systematic reviewers consider 
core outcome sets when registering their topics with 
Cochrane review groups or PROSPERO (international 
prospective register of systematic reviews). Systematic 
reviewers can identify if relevant core outcome sets 
exist for their review area by searching the publically 
accessible COMET (Core Outcome Measures in 
Effectiveness Trials) database.9
Inclusion and exclusion criteria
Reviewers should not exclude studies from their review 
on the basis of whether the outcomes of interest were 
reported, because non-reporting does not necessarily 
mean that the outcomes were not measured.5 This 
recommendation also forms part of the mandatory 
methodological standards (item C40) for the conduct 
of new Cochrane intervention reviews (Methodological 
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Summary poIntS
•   Outcome reporting bias occurs when trialists select for publication a subset of 
the original recorded outcomes based on knowledge of the results. Outcome 
reporting bias is a threat to evidence based medicine and contributes to waste 
in research
•   Empirical evidence suggests that statistically significant outcomes have 
higher odds of being fully reported than non-significant outcomes (odds ratios 
ranging from 2.2 to 4.7)
•   The ORBIT (Outcome Reporting Bias in Trials) research programme offers tools 
for systematic reviewers to identify missing outcome data, and assess and 
adjust for outcome reporting bias. A tutorial is provided to show how these 
tools could be used in a systematic review
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Expectations of Cochrane Intervention Reviews).10 
Despite these recommendations and recent screening 
initiatives introduced by the Cochrane Editorial Unit, a 
quarter of Cochrane reviews are still excluding studies 
because of missing relevant outcome data.11
We strongly encourage systematic reviewers to 
include relevant studies in their review irrespective 
of whether the studies reported any of the review 
outcomes of interest, and to assess those studies in 
accordance with the methods described below.
Identifying missing outcome data in reviews
An outcome matrix was proposed to help identify 
missing study outcome data.5 Reviewers can construct 
the matrix with the outcomes of interest in the review, 
with those reported in the trial reports listed in the 
columns and the different studies listed in the rows. An 
example of an outcome matrix for a Cochrane systematic 
review, “Topiramate add-on for drug-resistant partial 
epilepsy,”12 is presented in figure 1. When this review 
was undertaken, there was no core outcome set that 
covered the scope of the review; therefore, the choice 
of outcomes was left to the discretion of the review 
authors. The aim of the review was to evaluate the 
efficacy and tolerability of topiramate when used as an 
add-on treatment for people with drug resistant partial 
epilepsy. The review considered two benefit and 12 
harm outcomes. Eleven studies were included, while 
the review authors excluded one further study because 
there were “no relevant outcome data.” According 
to our earlier recommendation, the review authors 
should not have excluded this study (“Coles 1999”) 
from the review; we include this study in the example 
to provide a retrospective assessment of the impact of 
outcome reporting bias in this review. The outcome 
matrix, similar to the one presented in figure  1, 
provides a transparent way for systematic reviewers 
to show the outcomes that are reported for each study 
in the review, and those that are missing or partially 
reported. Partial reporting of outcome data refers to 
those that are inadequately reported for inclusion in 
a review meta-analysis (for example, an effect size 
was presented with no measure of precision or exact 
P value).
For trials that do not or partially report on 
outcomes, the matrix allows reviewers to assess the 
risk of outcome reporting bias according to the ORBIT 
classification system (see next section below). In the 
epilepsy example in figure 1, we can see from the 
matrix that all studies (apart from the excluded Cole 
1999 study) reported data on 50% reduction in seizure 
frequency but only six of the studies fully reported 
data on seizure freedom. These two outcomes are 
structurally related; so if a trial author reports on one 
of these outcomes, this suggests that the trialist must 
have also measured the other outcome.
We strongly encourage systematic reviewers to 
include an outcome matrix in their reviews. The ORBIT 
matrix generator, available on the ORBIT website,13 is 
a tool that researchers can easily use to construct an 
ORBIT outcome matrix, which researchers can also 
export for inclusion in a systematic review article.
obtaining unpublished information
Sources for obtaining unpublished information on 
clinical trials for use in systematic reviews have 
previously been described.14 These sources (for 
example, trial registry and regulatory agency databases, 
trialist and sponsor contact, litigation documents, 
conference abstracts, and internet searches) can help 
identify unreported outcomes in published trials. To 
minimise the amount of missing data in reviews, we 
* In epilepsy, treatment withdrawal reflects benet and harm–that is, withdrawal from treatment due to recurrent seizures on treatment (lack of benet) and/or withdrawal due to adverse events (harm).
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Fig 1 | Outcome matrix for review on topiramate add-on use for drug resistant partial epilepsy, with letters indicating ORBIT (Outcome Reporting Bias 
In Trials) classifications 
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recommend that reviewers should attempt to obtain as 
much missing outcome data as possible. Reviewers can 
then update the outcome matrix to reflect information 
obtained from unpublished sources.
Detecting outcome reporting bias
When no usable missing outcome data can be obtained 
from the sources given above, the ORBIT researchers 
developed classification systems to help systematic 
reviewers detect outcome reporting bias in reviews. 
The method relies only on information in the published 
trial report (for example, inconsistencies between 
sections such as the abstract, methods, and results), 
expert clinical judgment, and an assessment of the 
outcomes that researchers usually report across a set 
of trials in a review.5 The ORBIT researchers showed 
that the classification systems are able to detect bias 
with high sensitivity, even without access to other 
source documents to help perform the assessment, 
such as trial registry entries and study protocols.5 The 
classifications can also help reviewers judge the level 
of risk of bias within the “selective reporting outcome” 
domain by using the risk of bias tool currently used by 
the Cochrane Collaboration.15 Trials not reporting or 
partially reporting a review outcome should be labelled 
high risk, low risk, or no risk according to ORBIT 
terminology for benefit outcomes (table 1) or harm 
outcomes (table 2). The two classification systems 
identify whether: there is evidence that the trialist 
measured and analysed (or compared) the outcomes; 
the trialist measured but did not necessarily analyse 
(or compare) the outcomes; it is unclear whether the 
trialist measured the outcomes; or it is clear that the 
trialist did not measure the outcomes.
For the epilepsy review, the classifications given 
for each outcome with missing or partially reported 
data are presented in the outcome matrix (fig 1), 
with a full justification of each classification listed in 
supplementary table 1, and if appropriate verbatim 
text taken from the trial report. These justifications 
can also be included in systematic reviews to support 
the risk of bias assessment. For example, in Cochrane 
reviews, authors are encouraged to provide “support 
for judgment” on each risk of bias judgment made.
To assess the risk of bias due to selective reporting, 
we recommend that the ORBIT classification system 
is used by systematic reviewers as a framework to 
determine whether there is a high or low risk of outcome 
reporting bias when review outcome data are missing 
or partially reported. We also recommend that the 
assessment is completed by at least two independent 
researchers and differences discussed to agree on 
an overall classification (in the epilepsy review, 
assessments were completed by two methodologists 
and a clinical neurologist).
adjusting for outcome reporting bias in systematic 
reviews
Copas and colleagues developed new statistical 
sensitivity approaches for assessing the robustness 
of review meta-analysis conclusions when outcome 
reporting bias is suspected.16 The Copas method takes 
into account the relative sample size of the studies 
with missing outcome data and directly models the 
mechanism of outcome reporting bias for benefit and 
harm outcomes. The Copas method is particularly 
attractive because it uses the high and low risk of 
bias classifications already assigned using the ORBIT 
system.
We return to our epilepsy example given earlier, for 
which the outcome matrix of the ORBIT classification 
is shown in figure 1. The Copas method can be 
implemented on a user friendly platform for fixed 
effects meta-analyses for binary data through the 
ORBIT website.17 Full instructions on how to set up 
the data frame and use this method in 10 simple steps 
Table 1 | The ORBIT (Outcome Reporting Bias In Trials) classification system for missing or incomplete outcome 
reporting in benefit outcomes. Figure 1 uses these classifications5
ORBIT classification Description Level of reporting Risk of bias*
Clear that the outcome was measured and analysed
 A Trial report states that outcome was analysed but only reports that result was not significant (typically stating P>0.05) Partial High risk
 B Trial report states that outcome was analysed but only reports that result was significant (typically stating P<0.05) Partial No risk
 C
Trial report states that outcome was analysed but insufficient data were  
presented for the trial to be included in meta-analysis or to be considered to  
be fully tabulated
Partial Low risk
 D Trial report states that outcome was analysed but no results reported None High risk
Clear that the outcome was measured
 E Clear that the outcome was measured. Judgment says outcome likely to have been analysed but not reported because of non-significant results None High risk
 F Clear that the outcome was measured. Judgment says outcome unlikely to have been analysed None Low risk
Unclear whether the outcome was measured
 G Not mentioned but clinical judgment says likely to have been measured and analysed but not reported on the basis of non-significant results None High risk
 H Not mentioned but clinical judgment says unlikely to have been measured at all None Low risk
Clear that the outcome was not measured
 I Clear that the outcome was not measured NA No risk
NA=not appropriate.
*Risk of bias arising from the lack of inclusion of non-significant results when a trial was excluded from a meta-analysis or not fully reported in a review 
because the data were unavailable.
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are available on the website.17 The data frame for the 
epilepsy example can also be downloaded from the 
website. The method can be applied to other data 
types and random effects meta-analyses—the study 
team are currently working on implementing this on 
the same user friendly platform. Further support on 
using the Copas method and interpreting the data 
can be accessed through the “Contact” page of our 
website.17 18
After applying the Copas bias adjustments for 
partially reported or unreported outcomes (table 
3), the review had overestimated the benefits and 
underestimated the harms of the test treatment.16 
The adjustment was greater for the harm outcomes, 
for which fewer studies reported the outcomes of 
interest, and less of a concern for the benefit outcomes, 
for which there were fewer missing outcomes. For 
example, when considering the harm outcome nausea 
and vomiting, the unadjusted estimate (relative risk 
1.50, 95% confidence interval 0.71 to 3.15) reported 
in the review suggested no statistically significant 
difference between treatments. However, the Copas 
estimate after adjustment for outcome reporting bias 
(1.90, 1.08 to 3.59) suggested statistically significantly 
more harm in the treatment arm.
When outcome reporting bias is suspected, we 
recommend that the quality of evidence is lowered 
in relation to the standard GRADE (Grades of 
Recommendation, Assessment, Development and 
Evaluation) assessment applied in reviews. We also 
recommend that sensitivity analyses are performed 
for important outcomes to assess the robustness of 
conclusions to outcome reporting bias.16
Conclusions
Empirical evidence suggests that outcome reporting 
bias is a threat to the validity of the evidence base and 
contributes to research waste. We have highlighted 
up-to-date approaches and recommendations for 
detecting this problem and adjusting the results when 
performing sensitivity analyses in systematic reviews. 
We anticipate continued application of these methods 
and methodological research into the assessment and 
adjustment of outcome reporting bias in the years 
to come. The ORBIT website is a useful resource, 
providing researchers with tools to detect outcome 
reporting bias and methods for sensitivity analysis; it 
is also a repository for important publications in this 
field.
Contributors: The authors include statisticians and a clinical 
epidemiologist with expertise in outcome reporting bias and a 
Table 2 | The ORBIT II (Outcome Reporting Bias In Trials II) classification system for missing or incomplete outcome 
reporting in harm outcomes. Figure 1 uses these classifications6
ORBIT II classification Description Level of reporting Risk of bias*
Explicit specific harm outcome: measured and compared across treatment groups 
 P1 States outcome analysed but reported only that P>0.05 Partial High risk
 P2 States outcome analysed but reported only that P<0.05 Partial High risk
 P3 Insufficient reporting for meta-analysis or full tabulation Partial Low risk
Explicit specific harm outcome: measured but not compared across treatment groups
 Q Clear that outcome was measured and clear outcome was not compared NA No risk
Explicit specific harm outcome: measured, not clear whether compared or not across treatment groups
 R1 Clear that outcome was measured but no results reported None High risk
 R2 Result reported globally across all groups None High risk
 R3 Result reported from some groups only None High risk
Specific harm outcome not explicitly mentioned: clinical judgment says likely measured and likely compared across treatment groups 
 S1 Only pooled adverse events reported (could include specific harm outcome) None High risk
 S2 No harms mentioned or reported None High risk
Specific harm outcome not explicitly mentioned: clinical judgment says likely measured but no events
 T1 Specific harm not mentioned but all other specific harms fully reported None Low risk
 T2 No description of specific harms None Low risk
Specific harm outcome not explicitly mentioned, clinical judgment says unlikely measured
 U No harms mentioned or reported None Low risk
Explicit the specific harm outcome was not measured 
 V Report clearly specifies that data on the specific harm of interest were not 
measured
NA No risk
NA=not appropriate.
*Bias would occur if specific harm had been measured, but data were presented or suppressed in a way that would mask the harm profile of particular 
interventions.
Table 3 | Risk assessment of add-on use of topiramate for drug resistant partial  
epilepsy, accounting for partially reported and unreported study outcomes. Data are 
 Mantel-Haenszel estimates and confidence intervals, unadjusted and adjusted for 
outcome reporting bias (using the Copas method)16
Outcome
Pooled estimate, relative risk (95% CI)
Unadjusted Copas adjustment
Benefits 
 50% seizure reduction 2.97 (2.38 to 3.72) 2.87 (2.31 to 3.57)
 Seizure freedom 3.41 (1.37 to 8.51) 2.66 (1.19 to 5.78)
Harms
 Treatment withdrawal 2.44 (1.45 to 4.10) 2.47 (1.48 to 4.13)
 Dizziness 1.54 (1.07 to 2.22) 1.64 (1.16 to 2.32)
 Headache 0.99 (0.67 to 1.44) 1.14 (0.83 to 1.58)
 Nausea and vomiting 1.50 (0.71 to 3.15) 1.90 (1.08 to 3.59)
 Paraesthesias 3.91 (1.51 to 10.12) 4.40 (1.87 to 10.83)
 Weight loss 3.47 (1.55 to 7.79) 3.60 (1.69 to 7.92)
 Fatigue 2.19 (1.42 to 3.40) 2.22 (1.46 to 3.42)
 Somnolence 2.29 (1.49 to 3.51) 2.35 (1.55 to 3.57)
 Concentration impairment 7.81 (2.08 to 29.29) 8.25 (2.45 to 29.89)
 Speech difficulty 3.37 (0.80 to 14.13) 4.48 (1.55 to 16.01)
 Thinking abnormality 5.70 (2.26 to 14.38) 6.02 (2.54 to 14.79)
 Ataxia 2.29 (1.10 to 4.77) 2.61 (1.36 to 5.16)
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